COR Stock Analysis — Cencora
Sector: Healthcare Distribution
AI Verdict
Cencora trades at 16.2x next year's earnings with triple-digit EPS growth expected, making it cheap for the growth on offer if its entrenched distribution moat holds and execution matches forecasts.
Competitive Moat
Cencora operates as a pharmaceutical distributor, leveraging scale and logistics networks to secure exclusive supply agreements with manufacturers and healthcare providers. Its defensibility comes from entrenched relationships and regulatory complexity, which create high switching costs for customers.
Summary
Cencora's stock is deeply oversold with an RSI of 22.1 and a forward P/E of just 16.2x despite analyst consensus for 100.4% EPS growth next year.
Where It Stands
Shares have dropped -6.48% over the past year, trade at 16.2x next year's earnings (vs. the healthcare sector median of 22x), and the RSI of 22.1 signals extreme oversold territory.
Key Metrics
- RSI: 22.1 — Oversold
- Trailing P/E: 32.5x
- Forward P/E: 16.2x
- PEG Ratio: 0.32
- Earnings Growth: +1.0%
- Revenue Growth: +0.1%
- Market Cap: $11.5B
- Dividend Yield: 0.01%
- 1-Year Return: -6.48%
- 52-Week High: $377.54
- 52-Week Low: $244.82
Analyst Consensus
15 Buy · 4 Hold · 0 Sell (19 analysts)
Bull Case
The combination of a 16.2x forward P/E and 100.4% expected EPS growth means you're paying a low price for a potential earnings rebound if forecasts are accurate.
Bear Case
If the forward P/E reverts even halfway back to the sector median of 22x without the expected EPS surge, the stock could see further downside from its already -6.48% 1-year return.
Catalyst to Watch
Next earnings report — if Cencora delivers on the 100.4% EPS growth expectation, the valuation gap could close quickly.